Valuation Update With 7 Day Price Move • Jun 30
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹2,802, the stock trades at a trailing P/E ratio of 43.2x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 778% over the past three years. New Risk • Jun 29
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 13% per year over the past 5 years. High level of non-cash earnings (24% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change). Board Change • Jun 10
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 3 experienced directors. 5 highly experienced directors. 4 independent directors (5 non-independent directors). Independent Director Vinod Sharma was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • May 20
Full year 2026 earnings released: EPS: ₹64.90 (vs ₹38.40 in FY 2025) Full year 2026 results: EPS: ₹64.90 (up from ₹38.40 in FY 2025). Revenue: ₹5.06b (up 37% from FY 2025). Net income: ₹673.5m (up 69% from FY 2025). Profit margin: 13% (up from 11% in FY 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has increased by 93% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • May 19
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹1,999, the stock trades at a trailing P/E ratio of 36.7x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 575% over the past three years. Announcement • May 08
Kwality Pharmaceuticals Limited to Report Q4, 2026 Results on May 19, 2026 Kwality Pharmaceuticals Limited announced that they will report Q4, 2026 results on May 19, 2026 Valuation Update With 7 Day Price Move • Apr 20
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹1,747, the stock trades at a trailing P/E ratio of 32.1x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 410% over the past three years. Reported Earnings • Feb 14
Third quarter 2026 earnings released: EPS: ₹15.42 (vs ₹8.21 in 3Q 2025) Third quarter 2026 results: EPS: ₹15.42 (up from ₹8.21 in 3Q 2025). Revenue: ₹1.24b (up 47% from 3Q 2025). Net income: ₹160.1m (up 88% from 3Q 2025). Profit margin: 13% (up from 10% in 3Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has increased by 62% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Feb 12
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹1,362, the stock trades at a trailing P/E ratio of 28.8x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 305% over the past three years. Board Change • Feb 09
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Director Vinod Sharma was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Feb 02
Kwality Pharmaceuticals Limited to Report Q3, 2026 Results on Feb 12, 2026 Kwality Pharmaceuticals Limited announced that they will report Q3, 2026 results on Feb 12, 2026 New Risk • Jan 14
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 11% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (6.8% average weekly change). Valuation Update With 7 Day Price Move • Dec 23
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₹1,128, the stock trades at a trailing P/E ratio of 23.9x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 204% over the past three years. Reported Earnings • Nov 14
Second quarter 2026 earnings released: EPS: ₹13.60 (vs ₹8.15 in 2Q 2025) Second quarter 2026 results: EPS: ₹13.60 (up from ₹8.15 in 2Q 2025). Revenue: ₹1.12b (up 24% from 2Q 2025). Net income: ₹141.2m (up 67% from 2Q 2025). Profit margin: 13% (up from 9.4% in 2Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 41% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Nov 05
Kwality Pharmaceuticals Limited to Report Q2, 2026 Results on Nov 13, 2025 Kwality Pharmaceuticals Limited announced that they will report Q2, 2026 results on Nov 13, 2025 New Risk • Oct 16
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₹8.79b (US$99.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 7.7% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₹8.79b market cap, or US$99.9m). Announcement • Sep 11
Kwality Pharmaceuticals Limited Approves Appointment of Vinod Kumar Sharma as Independent Director Kwality Pharmaceuticals Limited at its AGM held on September 9, 2025, approved appointment of Mr. Vinod Kumar Sharma as an Independent Director of the Company. New Risk • Aug 19
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.1% average weekly change). Earnings have declined by 7.7% per year over the past 5 years. Announcement • Aug 18
Kwality Pharmaceuticals Limited, Annual General Meeting, Sep 09, 2025 Kwality Pharmaceuticals Limited, Annual General Meeting, Sep 09, 2025, at 12:00 Indian Standard Time. Reported Earnings • Aug 12
First quarter 2026 earnings released: EPS: ₹11.49 (vs ₹8.04 in 1Q 2025) First quarter 2026 results: EPS: ₹11.49 (up from ₹8.04 in 1Q 2025). Revenue: ₹1.12b (up 40% from 1Q 2025). Net income: ₹119.3m (up 43% from 1Q 2025). Profit margin: 11% (in line with 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has increased by 52% per year, which means it is well ahead of earnings. Announcement • Aug 05
Kwality Pharmaceuticals Limited to Report Q1, 2026 Results on Aug 11, 2025 Kwality Pharmaceuticals Limited announced that they will report Q1, 2026 results on Aug 11, 2025 Valuation Update With 7 Day Price Move • Jul 04
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹1,177, the stock trades at a trailing P/E ratio of 30.6x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 293% over the past three years. Valuation Update With 7 Day Price Move • Jun 16
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹1,087, the stock trades at a trailing P/E ratio of 28.3x. Average trailing P/E is 34x in the Pharmaceuticals industry in India. Total returns to shareholders of 217% over the past three years. Reported Earnings • May 23
Full year 2025 earnings released: EPS: ₹38.36 (vs ₹22.93 in FY 2024) Full year 2025 results: EPS: ₹38.36 (up from ₹22.93 in FY 2024). Revenue: ₹3.72b (up 21% from FY 2024). Net income: ₹398.5m (up 67% from FY 2024). Profit margin: 11% (up from 7.7% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has increased by 31% per year, which means it is well ahead of earnings. New Risk • May 20
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.7% average weekly change). Earnings have declined by 0.03% per year over the past 5 years. Valuation Update With 7 Day Price Move • May 20
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to ₹955, the stock trades at a trailing P/E ratio of 33.3x. Average trailing P/E is 32x in the Pharmaceuticals industry in India. Total returns to shareholders of 129% over the past three years. Valuation Update With 7 Day Price Move • Mar 26
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹807, the stock trades at a trailing P/E ratio of 28.1x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 35% over the past three years. New Risk • Mar 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.03% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Market cap is less than US$100m (₹7.31b market cap, or US$84.0m). Reported Earnings • Feb 01
Third quarter 2025 earnings released: EPS: ₹8.21 (vs ₹7.39 in 3Q 2024) Third quarter 2025 results: EPS: ₹8.21 (up from ₹7.39 in 3Q 2024). Revenue: ₹850.6m (up 8.9% from 3Q 2024). Net income: ₹85.3m (up 11% from 3Q 2024). Profit margin: 10.0% (in line with 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 85 percentage points per year, which is a significant difference in performance. New Risk • Jan 27
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₹8.59b (US$99.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company. Reported Earnings • Nov 01
Second quarter 2025 earnings released: EPS: ₹8.15 (vs ₹5.99 in 2Q 2024) Second quarter 2025 results: EPS: ₹8.15 (up from ₹5.99 in 2Q 2024). Revenue: ₹902.6m (up 30% from 2Q 2024). Net income: ₹84.7m (up 36% from 2Q 2024). Profit margin: 9.4% (up from 9.0% in 2Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance. Valuation Update With 7 Day Price Move • Oct 31
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹932, the stock trades at a trailing P/E ratio of 36.2x. Average trailing P/E is 38x in the Pharmaceuticals industry in India. Total returns to shareholders of 1.9% over the past three years. Announcement • Oct 23
Kwality Pharmaceuticals Limited to Report Q2, 2025 Results on Oct 30, 2024 Kwality Pharmaceuticals Limited announced that they will report Q2, 2025 results on Oct 30, 2024 New Risk • Sep 16
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (41% net debt to equity). Share price has been volatile over the past 3 months (8.1% average weekly change). Market cap is less than US$100m (₹8.04b market cap, or US$95.9m). Valuation Update With 7 Day Price Move • Aug 20
Investor sentiment improves as stock rises 28% After last week's 28% share price gain to ₹699, the stock trades at a trailing P/E ratio of 27.1x. Average trailing P/E is 37x in the Pharmaceuticals industry in India. Total returns to shareholders of 49% over the past three years. Reported Earnings • Aug 11
First quarter 2025 earnings released: EPS: ₹8.04 (vs ₹5.10 in 1Q 2024) First quarter 2025 results: EPS: ₹8.04 (up from ₹5.10 in 1Q 2024). Revenue: ₹803.6m (up 19% from 1Q 2024). Net income: ₹83.6m (up 54% from 1Q 2024). Profit margin: 10% (up from 8.0% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings. Announcement • Aug 02
Kwality Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 10, 2024 Kwality Pharmaceuticals Limited announced that they will report Q1, 2025 results on Aug 10, 2024 Reported Earnings • May 24
Full year 2024 earnings released: EPS: ₹22.76 (vs ₹18.67 in FY 2023) Full year 2024 results: EPS: ₹22.76 (up from ₹18.67 in FY 2023). Revenue: ₹3.09b (up 23% from FY 2023). Net income: ₹238.0m (up 23% from FY 2023). Profit margin: 7.7% (in line with FY 2023). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has increased by 70% per year, which means it is well ahead of earnings. Announcement • May 10
Kwality Pharmaceuticals Limited to Report Q4, 2024 Results on May 23, 2024 Kwality Pharmaceuticals Limited announced that they will report Q4, 2024 results at 3:30 PM, Indian Standard Time on May 23, 2024 Valuation Update With 7 Day Price Move • Apr 05
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹479, the stock trades at a trailing P/E ratio of 41.5x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 755% over the past three years. Reported Earnings • Feb 08
Third quarter 2024 earnings released: EPS: ₹7.39 (vs ₹6.82 in 3Q 2023) Third quarter 2024 results: EPS: ₹7.39 (up from ₹6.82 in 3Q 2023). Revenue: ₹781.0m (up 39% from 3Q 2023). Net income: ₹76.9m (up 8.3% from 3Q 2023). Profit margin: 9.8% (down from 13% in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has increased by 106% per year, which means it is well ahead of earnings. Board Change • Feb 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 1 experienced director. 8 highly experienced directors. Non-Executive & Independent Director Prashanth Vellanki was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Jan 26
Kwality Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 06, 2024 Kwality Pharmaceuticals Limited announced that they will report Q3, 2024 results on Feb 06, 2024 Announcement • Oct 18
Kwality Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 04, 2023 Kwality Pharmaceuticals Limited announced that they will report Q2, 2024 results on Nov 04, 2023 Announcement • Sep 07
Kwality Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2023 Kwality Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2023, at 12:00 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Standalone Financial Statements of the Company for the Financial Year ended 31 March, 2023, together with Reports of the Board of Directors and Auditors' thereon; to consider the Audited Consolidated Financial Statements of the Company for the Financial Year ended 31 March, 2023 and the Report of the Auditors thereon; to appoint a Director in place of Mr. AJAY KUMAR ARORA, liable to retire by rotation in terms of Section 152(6) of the Companies Act, 2013 and being eligible, offers himself for reappointment; to appoint a Director in place of Mr. ADITYA ARORA, liable to retire by rotation in terms of Section 152(6) of the Companies Act,2013 and being eligible, offers himself for re- appointment; and to consider other matters. Reported Earnings • Aug 11
First quarter 2024 earnings released: EPS: ₹5.10 (vs ₹9.99 in 1Q 2023) First quarter 2024 results: EPS: ₹5.10 (down from ₹9.99 in 1Q 2023). Revenue: ₹678.5m (down 3.4% from 1Q 2023). Net income: ₹54.2m (down 49% from 1Q 2023). Profit margin: 8.0% (down from 15% in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 121% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Aug 03
Kwality Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 10, 2023 Kwality Pharmaceuticals Limited announced that they will report Q1, 2024 results on Aug 10, 2023 New Risk • Jul 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (51% net debt to equity). Share price has been volatile over the past 3 months (7.1% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (7.7% net profit margin). Market cap is less than US$100m (₹3.58b market cap, or US$43.6m). Reported Earnings • May 30
Full year 2023 earnings released: EPS: ₹18.16 (vs ₹116 in FY 2022) Full year 2023 results: EPS: ₹18.16 (down from ₹116 in FY 2022). Revenue: ₹2.54b (down 45% from FY 2022). Net income: ₹193.7m (down 84% from FY 2022). Profit margin: 7.6% (down from 26% in FY 2022). Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has increased by 100% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Apr 26
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹370, the stock trades at a trailing P/E ratio of 10.4x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 920% over the past three years. Reported Earnings • Feb 19
Third quarter 2023 earnings released: EPS: ₹6.82 (vs ₹15.20 in 3Q 2022) Third quarter 2023 results: EPS: ₹6.82 (down from ₹15.20 in 3Q 2022). Revenue: ₹565.5m (down 37% from 3Q 2022). Net income: ₹71.0m (down 55% from 3Q 2022). Profit margin: 13% (down from 18% in 3Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has increased by 116% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Dec 26
Investor sentiment improved over the past week After last week's 16% share price gain to ₹419, the stock trades at a trailing P/E ratio of 9.5x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 1,538% over the past three years. Board Change • Nov 22
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 5 experienced directors. 3 highly experienced directors. 4 independent directors (5 non-independent directors). Independent Director Kartik Kapur was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Announcement • Nov 20
Kwality Pharmaceuticals Limited Announces the Resignation of Sachin Seth as Non- Executive and Non Independent Director Kwality Pharmaceuticals Limited announced that Mr. Sachin Seth, Non- Executive & Non Independent Director of the company has resigned from the post of Director of the company with effect from November 18, 2022 due to other professional commitments. Reported Earnings • Nov 19
Second quarter 2023 earnings released: EPS: ₹8.82 (vs ₹57.33 in 2Q 2022) Second quarter 2023 results: EPS: ₹8.82 (down from ₹57.33 in 2Q 2022). Revenue: ₹569.3m (down 69% from 2Q 2022). Net income: ₹93.9m (down 84% from 2Q 2022). Profit margin: 17% (down from 32% in 2Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has increased by 130% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Sep 15
Investor sentiment improved over the past week After last week's 18% share price gain to ₹471, the stock trades at a trailing P/E ratio of 5.1x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 1,162% over the past three years. Valuation Update With 7 Day Price Move • Sep 01
Investor sentiment improved over the past week After last week's 20% share price gain to ₹352, the stock trades at a trailing P/E ratio of 3.8x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 760% over the past three years. Reported Earnings • Aug 18
First quarter 2023 earnings released First quarter 2023 results: Revenue: ₹706.0m (down 54% from 1Q 2022). Net income: ₹105.4m (down 78% from 1Q 2022). Profit margin: 15% (down from 31% in 1Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has only increased by 88% per year, which means it is significantly lagging earnings growth. Announcement • Aug 06
Kwality Pharmaceuticals Limited to Report Q1, 2023 Results on Aug 13, 2022 Kwality Pharmaceuticals Limited announced that they will report Q1, 2023 results on Aug 13, 2022 Announcement • May 31
Kwality Pharmaceuticals Limited Provides Earnings Guidance for the Fiscal Year 2023 Kwality Pharmaceuticals Limited provided earnings guidance for the fiscal year 2023. For the period, the company expects revenue to be in the range of INR 3,500 million and INR 4,000 million. Valuation Update With 7 Day Price Move • May 26
Investor sentiment improved over the past week After last week's 21% share price gain to ₹440, the stock trades at a trailing P/E ratio of 4.5x. Average trailing P/E is 20x in the Pharmaceuticals industry in India. Total returns to shareholders of 1,026% over the past three years. Announcement • May 20
Kwality Pharmaceuticals Limited to Report Fiscal Year 2022 Results on May 28, 2022 Kwality Pharmaceuticals Limited announced that they will report fiscal year 2022 results on May 28, 2022 Valuation Update With 7 Day Price Move • May 09
Investor sentiment deteriorated over the past week After last week's 15% share price decline to ₹411, the stock trades at a trailing P/E ratio of 4.2x. Average trailing P/E is 22x in the Pharmaceuticals industry in India. Total returns to shareholders of 950% over the past three years. Board Change • Apr 27
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 5 experienced directors. 3 highly experienced directors. 4 independent directors (5 non-independent directors). Independent Director Kartik Kapur was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Mar 23
Investor sentiment improved over the past week After last week's 22% share price gain to ₹468, the stock trades at a trailing P/E ratio of 4.8x. Average trailing P/E is 25x in the Pharmaceuticals industry in India. Total returns to shareholders of 1,164% over the past three years. Recent Insider Transactions • Feb 14
CFO & Whole Time Director recently bought ₹1.3m worth of stock On the 8th of February, Aditya Arora bought around 3k shares on-market at roughly ₹482 per share. This was the largest purchase by an insider in the last 3 months. This was Aditya's only on-market trade for the last 12 months. Valuation Update With 7 Day Price Move • Feb 04
Investor sentiment deteriorated over the past week After last week's 18% share price decline to ₹534, the stock trades at a trailing P/E ratio of 5.4x. Average trailing P/E is 25x in the Pharmaceuticals industry in India. Total returns to shareholders of 890% over the past three years. Valuation Update With 7 Day Price Move • Jan 03
Investor sentiment improved over the past week After last week's 15% share price gain to ₹940, the stock trades at a trailing P/E ratio of 9.5x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 1,578% over the past three years. Valuation Update With 7 Day Price Move • Jan 03
Investor sentiment improved over the past week After last week's 15% share price gain to ₹940, the stock trades at a trailing P/E ratio of 9.5x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 1,578% over the past three years. Valuation Update With 7 Day Price Move • Dec 02
Investor sentiment improved over the past week After last week's 17% share price gain to ₹862, the stock trades at a trailing P/E ratio of 8.8x. Average trailing P/E is 22x in the Pharmaceuticals industry in India. Total returns to shareholders of 1,424% over the past three years. Valuation Update With 7 Day Price Move • Oct 29
Investor sentiment improved over the past week After last week's 17% share price gain to ₹1,016, the stock trades at a trailing P/E ratio of 10.3x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 2,061% over the past three years. Reported Earnings • Oct 27
First half 2022 earnings released: EPS ₹90.57 (vs ₹6.70 in 1H 2021) The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2022 results: Revenue: ₹3.05b (up 154% from 1H 2021). Net income: ₹939.7m (up ₹870.2m from 1H 2021). Profit margin: 31% (up from 5.8% in 1H 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 98% per year but the company’s share price has increased by 183% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Sep 29
Investor sentiment improved over the past week After last week's 28% share price gain to ₹797, the stock trades at a trailing P/E ratio of 54.6x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 1,672% over the past three years. Valuation Update With 7 Day Price Move • Sep 15
Investor sentiment improved over the past week After last week's 16% share price gain to ₹562, the stock trades at a trailing P/E ratio of 38.5x. Average trailing P/E is 25x in the Pharmaceuticals industry in India. Total returns to shareholders of 1,178% over the past three years. Valuation Update With 7 Day Price Move • Aug 31
Investor sentiment deteriorated over the past week After last week's 19% share price decline to ₹383, the stock trades at a trailing P/E ratio of 26.2x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 770% over the past three years. Valuation Update With 7 Day Price Move • Jul 26
Investor sentiment improved over the past week After last week's 16% share price gain to ₹212, the stock trades at a trailing P/E ratio of 14.5x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 359% over the past three years. Reported Earnings • Jul 06
Full year 2021 earnings released: EPS ₹14.60 (vs ₹8.02 in FY 2020) The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2021 results: Revenue: ₹2.64b (up 85% from FY 2020). Net income: ₹151.5m (up 82% from FY 2020). Profit margin: 5.7% (down from 5.8% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has increased by 60% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Jun 25
Investor sentiment improved over the past week After last week's 32% share price gain to ₹138, the stock trades at a trailing P/E ratio of 13x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 188% over the past three years. Valuation Update With 7 Day Price Move • Apr 26
Investor sentiment improved over the past week After last week's 26% share price gain to ₹68.15, the stock trades at a trailing P/E ratio of 6.4x. Average trailing P/E is 22x in the Pharmaceuticals industry in India. Total returns to shareholders of 41% over the past three years. Valuation Update With 7 Day Price Move • Mar 24
Investor sentiment deteriorated over the past week After last week's 17% share price decline to ₹49.10, the stock trades at a trailing P/E ratio of 4.6x. Average trailing P/E is 18x in the Pharmaceuticals industry in India. Total returns to shareholders of 20% over the past three years. Is New 90 Day High Low • Jan 12
New 90-day high: ₹61.15 The company is up 2.0% from its price of ₹59.80 on 14 October 2020. The Indian market is up 24% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 10.0% over the same period. Valuation Update With 7 Day Price Move • Dec 28
Investor sentiment improved over the past week After last week's 18% share price gain to ₹58.00, the stock is trading at a trailing P/E ratio of 5.5x, up from the previous P/E ratio of 4.6x. This compares to an average P/E of 24x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years were flat. Valuation Update With 7 Day Price Move • Dec 21
Investor sentiment deteriorated over the past week After last week's 18% share price decline to ₹49.00, the stock is trading at a trailing P/E ratio of 4.6x, down from the previous P/E ratio of 5.7x. This compares to an average P/E of 24x in the Pharmaceuticals industry in India. Total return to shareholders over the past three years is a loss of 15%. Is New 90 Day High Low • Dec 21
New 90-day low: ₹49.00 The company is down 12% from its price of ₹55.50 on 15 September 2020. The Indian market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 7.0% over the same period. Announcement • Nov 08
Kwality Pharmaceuticals Limited to Report First Half, 2021 Results on Nov 13, 2020 Kwality Pharmaceuticals Limited announced that they will report first half, 2021 results on Nov 13, 2020 Announcement • Nov 06
Kwality Pharmaceuticals Limited, Annual General Meeting, Nov 30, 2020 Kwality Pharmaceuticals Limited, Annual General Meeting, Nov 30, 2020, at 11:30 Indian Standard Time. Location: VILLAGE NAGKALAN, MAJITHA ROAD, Amritsar Punjab India Agenda: To receive, consider and adopt the Audited Standalone and and the Rep Financial Statements of the Company for the Financial Year ended 31 March 2020; to appoint a Director in place of Mr. Ajay Kumar Arora and Mrs. Geeta Arora, liable to retire by rotation terms of Section 152(6) of the Companies Act, 2013 and being eligible, offers himself for re-appointment; and to ratification Of Cost Auditors Remuneration. Announcement • Jul 05
Kwality Pharmaceuticals Limited to Report Second Half, 2020 Results on Jul 13, 2020 Kwality Pharmaceuticals Limited announced that they will report second half, 2020 results on Jul 13, 2020 
